BANB 📈 Bachem Holding - Overview

Bachem Holding AG operates as a global provider of products and services for the pharmaceutical and biotechnology industries, supporting research, clinical development, and commercial applications. The company's expertise lies in the development, production, and regulatory support of peptide active pharmaceutical ingredients, including peptide and oligonucleotide new chemical entities (NCEs). This involves creating complex molecules that serve as the foundation for various medications, which are then used to treat a wide range of diseases and conditions.

Through its subsidiaries, Bachem Holding AG offers a comprehensive portfolio of services, including project management, quality and regulatory support, analytical services, and good manufacturing practice (GMP) production. The company also provides research grade production and supply chain management, ensuring a seamless integration of its services to support clients' needs. Additionally, Bachem Holding AG supplies commercial NCEs and generics, further expanding its offerings to the pharmaceutical and biotechnology sectors. By providing these services, the company plays a critical role in the development and production of life-changing medications.

Founded in 1971, Bachem Holding AG has established itself as a reputable player in the industry, with its headquarters located in Bubendorf, Switzerland. The company's commitment to quality, innovation, and customer satisfaction has enabled it to build long-standing relationships with its clients worldwide. With a strong focus on research and development, Bachem Holding AG continues to expand its capabilities, staying at the forefront of the rapidly evolving pharmaceutical and biotechnology landscape. The company's website, https://www.bachem.com, provides further information on its products and services, while its ISIN, CH1176493729, identifies it as a common stock listed under the GICS Sub Industry: Commodity Chemicals.